Up 38% in a Month: Can Genfit's Stock Surge Continue?

A strong upward momentum, but signs of tension

Genfit's recent performance is certainly impressive. The stock of the Lille-based biotech company has surged nearly 40% from 6.18 euros just a month ago, continuing a more pronounced upward trajectory over three months (+84%) and one year (+152%). The share price is now well above its 20-day (7.95 euros), 50-day (6.44 euros), and 200-day (4.38 euros) moving averages, reinforcing the strength of the current trend. However, several indicators urge caution. The RSI at 70 has entered the overbought zone, historically signaling a risk of short-term pullback. Monthly volatility, measured at 16.55, reflects significant fluctuations, while the performance over the last seven days shows a decline of 3.22%, including a 2.12% drop in the current session alone. Additionally, the stock is trading close to its technical resistance identified at 9.09 euros, a level it has not yet managed to surpass.

For the Investor: Short-Term Potential Diminishing

While the underlying momentum undeniably remains favorable—with the stock trading nearly double its 200-day moving average—the immediate upside potential appears more limited. The resistance at 9.09 euros offers only about a 6% upside from the current price, whereas the technical support is at 5.50 euros, presenting a downside risk of over 35% in the event of a market downturn. Additionally, the negative beta of -0.21 indicates a disconnection from the market, a common feature of biotech stocks whose catalysts are primarily linked to company-specific events.

The upcoming major event is the release of the 2025 annual results, scheduled for April 2. This milestone could provide new insights into Genfit's financial trajectory and potentially reignite—or hinder—the current trend. In the near term, the combination of an overbought RSI, close technical resistance, and a slight decline over the past week suggests that a consolidation phase cannot be ruled out. Investors interested in this stock might find it prudent to wait for a potential dip toward support levels or, at the very least, the clarity expected from the annual earnings release in early April.